Draft guidance from NICE recommends durvalumab before and after surgery for muscle-invasive bladder cancer following phase 3 trial survival data.
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence for durvalumab, ...
USA: Researchers have drawn attention to an unusual but potentially distressing adverse effect linked to a commonly used postoperative treatment for non–muscle-invasive bladder cancer (NMIBC).
Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...
Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...
A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...
A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer ...
Senior male patient in hospital gown seen through CAT scan machine. Male patient at clinic for MRI scan. The 2023 guideline on managing muscle-invasive bladder cancer offers evidence-based ...
Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...
Some types and grades of bladder cancer spread quickly. Doctors can treat this disease in several ways. However, treatments are most effective before bladder cancer spreads. The bladder is a hollow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results